In a report released on December 5, David Risinger from SVB Securities maintained a Buy rating on HilleVax, Inc (HLVX – Research Report). The company’s shares closed yesterday at $16.10.
According to TipRanks, Risinger is a 4-star analyst with an average return of 3.7% and a 57.81% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Roivant Sciences.
The analyst consensus on HilleVax, Inc is currently a Moderate Buy rating.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.42 and a one-year low of $7.90. Currently, HilleVax, Inc has an average volume of 88.51K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Read More on HLVX: